Compass Therapeutics
Discovery and development teams that work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $80.0m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | - | (6456 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | (5809 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | - | - | 4981 % |
Source: Company filings or news article
Related Content
Compass Therapeutics is a biotechnology company focused on developing next-generation antibody therapeutics to treat cancer and autoimmune diseases. The company operates in the biopharmaceutical market, leveraging its proprietary platforms to identify and advance therapeutic leads with exceptional speed and diversity. Compass Therapeutics serves patients and healthcare providers by offering highly effective, precisely targeted therapies that bridge the innate and adaptive immune systems. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic candidates. Revenue is generated through partnerships, licensing agreements, and sales of approved therapies. The company is committed to innovation and collaboration, aiming to unlock the complexities of the immune system to develop groundbreaking treatments.
Keywords: biotechnology, antibody therapeutics, cancer, autoimmune diseases, immune synapse, biopharmaceutical, research, development, clinical trials, innovation.
Tech stack
Investments by Compass Therapeutics
Edit